Rapid Dose Therapeutics Corp. (DOSE.CN) Research

Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.

Market snapshot

Symbol
DOSE.CN
Price
$0.10
Day change
+18.75%
Market cap
$12.5M
P/E ratio
-2.86x
52-week range
0.08-0.24
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BriaCell Therapeutics Corp. (BCT.TO)
  • Britannia Life Sciences Inc. (BLAB.CN)
  • Gemina Laboratories Ltd. (GLAB.CN)
  • Greenway Greenhouse Cannabis Corporation (GWAY.CN)
  • Hemostemix Inc. (HEM.V)
  • Pharmala Biotech Holdings Inc. (MDMA.CN)
  • Pangenomic Health Inc. (NARA.CN)
  • PreveCeutical Medical Inc. (PREV.CN)

Open Rapid Dose Therapeutics Corp. (DOSE.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.